Monica Varano

Prof. Monica Varano

Pubblications: PubMed

Role: Scientific Direttor

Sub-specialties: Age-related Macular Degeneration (AMD), Hypovision and visual rehabilitation, Retinal Vein Occlusion, Macular pathology of surgical interest, Diabetic retinopathy,

Clinical activity: IRCCS Fondazione G.B. Bietti - Via Livenza 3 - Rome


Education

1984  Degree in Medicine and Surgery (110/110 cum laude), University “La Sapienza”, Rome
1988  Residency in Ophthalmology (70/70 cum laude) University “La Sapienza”, Rome
1989 Winner of the Fellowship in vitreo-retinal diseases at “Fondazione G.B.Bietti”
1993  Observership at the Ophthalmology Department of Laser and Angiography, University of Creteil,
Paris, Chief of the Department Prof. Gabriel Coscas.

Roles

  • Since 1991 to 2005 Researcher in the Medical Retina Department at the Foundation G.B. Bietti-IRCCS
    Fondazione G.B.Bietti-IRCCS
  • Since 2005 to 2014 Consultant in the Medical Retina Department at the Foundation G.B. Bietti-IRCCS
    Head of the Medical Retina Service at the Fondazione G.B.Bietti-IRCCS
    Fondazione G.B.Bietti-IRCCS, Via Livenza n 3 00198 Rome, Italy
  • Since 2008 to 2014 Head of the Maculopathy Center of Fondazione G.B. Bietti-IRCCS
    “Britannico Hospital” – ASL S. Giovanni Addolorata”, Via Santo Stefano Rotondo n 6-00184 Rome, Italy
  • Since 2014 Scientific Director Fondazione G.B. Bietti-IRCCS
  • Since 2016 Professor of Ophthalmology, University  of “Tor Vergata”, Rome  and  University “Campus Biomedico", Rome.
  • Since 2005 to 2014    Head of the Medical Retina Service at the Fondazione G.B.Bietti-IRCCS
  • 2011 President of S.I.R. (Italian Society of Retina)
  • 2014 Scientific Director IRCCS BIETTI
  • Since 2016 Professor of Ophthalmology  University “Tor Vergata "of Rome”  and  University “Campus Biomedico" of Rome .
  • Member of SOI (Italian Society of Ophthalmology)
  • Member of S.I.R. (Italian Society of Retina)
  • Member of The Association for Research in Vision and Ophthalmology (ARVO)
  • Member of Club Gonin
  • Member of Euretina
  • An open-label , multicenter study of the treatment of predominantly classic subfoveal  choroidal neovascularization secondary to age–related macular degeneration using photodynamic therapy with Verteporfin in Italy ( VIT )”
  • Open label multicenter randomized case-control clinical trial to evaluate the efficacy of the antioxidant therapy with Azyr in the early age related macular degeneration
  • A six-month, phase 3, multicenter, masked, randomized, sham-controlled trial (with six-month open label extension) to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with macular edema following central retinal vein occlusion or branch vein occlusion.
  • A 3 year, phase 3, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 and 350 Dexamethasone Posterior Segment Drug delivery System (DEXPSDDS) Applicator System in the treatment of patients with diabetic macular edema. ( Mead )
  • A 12-month randomized, double-masked, controlled, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Lucentis™ monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration ( Montblanc)
  • A 12  Months Case Series open study to assess the safety and efficacy of intravitreal injection of Lucentis(Ranibizumab 0.5 mg) used in combination with Visudyne (Verteporfin PDT) in naive subjects with subfoveal CNV secondary to AMD.(Luvi )
  • A randomized, double masked , active controlled , phase 3 study of the efficacy , safety and tolerability of repeteated doses of intravitreal VEGF trap-Eye in subjects with neovascular age-related macular degeneration ( AMD )
  • A phase II  prospective , randomised , multicentric diabetic macular edema  dose ranging , comparation study evaluating the efficacy and safety of PF- 04523655 versus laser therapy (DEGAS ) 2008-present
  • A randomized, double-masked, sham controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trat-Eye in subjects with macular edema secondary to central vein occlusion (CRVO) (GALILEO).
  • A Clinical Safety and Efficacy Comparison of  NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients (MIZAR )
  • A 2 years randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efiicacy and safety of 0.5 mg ranibizumab in two “treat and axtend” Treatment algorithms vs 0.5 mg ranibizumab as needed in patients with macular edema and visual Impairment secondary to Diabetes mellitus ( RETAIN)
  • A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreale VEGF Trap-Eye in subjects with diabetic macular edema ( VIVID)
  • A 12 month, multicentre, randomized parallel group study to compare the efficacy and safety of Ozurdex versus Lucentis in patients with branch retinal vein occlusion. ( COMO)
  • A 6-month, phase II, double masked, multicentre, randomized Placebo- controlled parallel group study to asses the safety and efficacy of topical administration of two concentration of FOV2304 (1% and 2%) twice daily for the treatment of center- involving clinically significant macular edema associated with Diabetic Retinopaty  ( FOVEA)
  • Identifying progression of retinal disease in eyes with NPDR in diabetes type 2 using non invasive procedures. ( EVI)
  • A multicentric open-label randomized study comparing the efficacy and safety of 700  g dexamethasone segment drug delivery system (DEX PS DDS) to ranibizumab in patients with diabetic macular edema ( LUZO )
  • An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.( CRFB002DIT01- PRIDE)
  • A retrospective non-interventional  study to assess the effectiveness of existing Anti‑vascUlar endothelial growth factor (anti‑VEGF) treatment  Regimens in patients with wet Age-related macular degeneration (Aura )
  • A 12-month, phase IIIb, randomized, visual acuity assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration” CRFB002A2411(Trend)
  • A 12-month, randomized, double-masked, sham-controlled,multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor(VEGF) driven choroidal neovascularization (CNV) (Minerva)
  • Prospective, randomized, multicenter, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus and PRP in monotherapy in the treatment of patients with high risk proliferative diabetic retinopathy. (PROTEUS)
  • A non-interventional study in patients with diabetic macula edema (DME) with central involvement to assess the effectiveness of existing anti vascular endothelial growth factor (anti-VEGF) treatment regimens ( Polaris )
  • Valutazione degli esiti anatomici e funzionali in pazienti trattati con ocriplasmina a causa di trazione vitreomaculare/adesione vitreomaculare sintomatica (VitreomacularTraction/Symptomatic Vitreomacular Adhesion, VMT/sVMA” ( Jetrea )
  • A 12 months, open-label, interventional, multicentre study to investigate the current criteria driving re-treatment with ranibizumab upon relapse in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia ( Olimpic )
  • A PHASE 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovista ( anti pdgf-b pegylated aptamer) administered in combination with Lucentis compared to lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration. ( Fovista )
  • Studio interventistico, >multicentrico, prospettico, in aperto, con un solo gruppo di trattamento, della durata di 12 mesi per valutare la sicurezza e la  tollerabilità di ranibizumab 0.5 mg in pazienti affetti da wAMD >mono/bilaterale in occhi con BCVA inferiore a 2/10 e/o patologia del  secondo occhio (Tweyes )
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal aflibercept - a randomized,open-label, active-controlled, parallel-group phase IV/IIIb study (ARIES)
  • An open-label, randomized, active-controlled,parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)- 16598_AMD_PAES_Protocol_Final_19Dec2014_AZURE
  • A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (AntiPDGF-B pegylatedaptamer) administered in combination with either Avastin® or Eylea® compared to Avastin® or Eylea® monotherapy in subjects with subfovealneovascular age-related macular degeneration
  • Aflibercept intravitreale per la neovascolarizzazione coroideale secondaria a Strie Angioidi (EYLEA-STRIE)
  • A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion” ( Centera )
  • AURIGA / An observationAl stUdy pRogram to InvestiGate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting IMPACT 19157

 

  • Acta Ophthalmologica
  • IOVS
  • BJO
  • European Journal of Ophthalmology
  • Ophthalmologica
  • AJO
  • Retina
  • Italian Review of Ophthalmology
  • Principal investigator in the research project aims for 2008 “identification of genetic determinants of diabetic retinopathy in patients with type 2 diabetes
  • Principal investigator in the research project aims for 2009 “Biomarkers of inflammation and innate immunity in diabetic retinopathy”
  • Professor of the Master in vitreo-retina. Polytechnic Univesity of Marche in 2009
  • Professor of the Master of second level . " Vitreoretinal pathology : from diagnosis to medical and surgical therapy ," Catholic University of Rome in 2011
  • Since 2014 Scientific Director IRCCS Fondazione Bietti
  • Best Paper SOI 2017
  • 2011 President of S.I.R. (Italian Society of Retina)